These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8053980)

  • 1. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
    Tanaka M; Yano S; Hasegawa Y; Nakao K
    Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
    Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
    Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
    Houjou T; Wada T; Yasutomi M
    Clin Ther; 1993; 15(1):137-47. PubMed ID: 8458043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
    Schieweck K; Bhatnagar AS; Matter A
    Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
    Iino Y; Karakida T; Sugamata N; Andoh T; Takei H; Takahashi M; Yaguchi S; Matsuno T; Takehara M; Sakato M; Kawashima S; Morishita Y
    Anticancer Res; 1998; 18(1A):171-6. PubMed ID: 9568073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
    Yamamoto T; Urabe M; Tamura T; Kitawaki J; Honjo H; Okada H
    Anticancer Res; 1991; 11(6):1999-2002. PubMed ID: 1776832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
    Nishino Y; Schneider MR; Michna H; el Etreby MF
    J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
    Sugamata N; Koibuchi Y; Iino Y; Morishita Y
    Int J Oncol; 1999 Feb; 14(2):259-63. PubMed ID: 9917500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats.
    Yano S; Ikegami Y; Nakao K
    Arzneimittelforschung; 1996 Feb; 46(2):192-5. PubMed ID: 8720312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
    Yue W; Wang J; Savinov A; Brodie A
    Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
    Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
    J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
    Brueggemeier RW; Li PK
    Cancer Res; 1988 Dec; 48(23):6808-10. PubMed ID: 3141048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
    De Coster R; Van Ginckel RF; Callens MJ; Goeminne NK; Janssens BL
    Cancer Res; 1992 Mar; 52(5):1240-4. PubMed ID: 1737385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
    Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
    Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
    Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
    Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
    Tekmal RR; Durgam VR
    Cancer Lett; 1997 Sep; 118(1):21-8. PubMed ID: 9310256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer.
    Thun-Battersby S; Mevissen M; Löscher W
    Cancer Res; 1999 Aug; 59(15):3627-33. PubMed ID: 10446973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
    Wing LY; Garrett WM; Brodie AM
    Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
    Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
    Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
    J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.